西班牙Certest溶血性A鏈球菌抗體

廣州健侖生物科技有限公司

廣州健侖長(zhǎng)期供應(yīng)各種生物原料，主要代理品牌：西班牙Certest。

主要產(chǎn)品包括各種生物單克隆抗原抗體、重組蛋白。

西班牙Certest溶血性A鏈球菌抗體

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

【產(chǎn)品介紹】

西班牙

癌癥，雖然總是帶著危險(xiǎn)的，但真正對(duì)生命造成威脅的是當(dāng)癌細(xì)胞開始擴(kuò)散到不同的領(lǐng)域和遍及全身時(shí)。現(xiàn)在，美國(guó)密蘇里大學(xué)(MU)的研究人員發(fā)現(xiàn)，由細(xì)菌用作通訊系統(tǒng)的一個(gè)分子可以被操縱來阻止癌細(xì)胞擴(kuò)散。MU獸醫(yī)醫(yī)學(xué)院比較腫瘤學(xué)和表觀遺傳學(xué)實(shí)驗(yàn)室的助理研究教授和副主任Senthil Kumar說，這個(gè)通訊系統(tǒng)可用于“告訴”癌細(xì)胞如何行動(dòng)，甚至是死亡的命令。
“在感染期間，細(xì)菌會(huì)釋放出分子，使得它們能夠彼此‘交談’，” Kumar說，他了這項(xiàng)研究。“所述信號(hào)根據(jù)釋放分子的類型，告訴其他細(xì)菌繁殖，逃避免疫系統(tǒng)甚至停止蔓延。我們發(fā)現(xiàn)，如果我們將‘停止蔓延’的細(xì)菌分子引入癌細(xì)胞中，這些細(xì)胞不但會(huì)停止擴(kuò)散，而且它們也將會(huì)開始死亡。”
這項(xiàng)研究發(fā)表于《PLoS ONE》雜志上，Kumar，以及合著者、MU獸醫(yī)醫(yī)學(xué)院的副教授杰弗里·布萊恩，使用稱為ODDHSL的細(xì)菌通訊分子用來治療在培養(yǎng)基中生長(zhǎng)的人胰腺癌細(xì)胞。經(jīng)過治療后，人胰腺癌細(xì)胞停止繁殖，未能遷移并開始死亡。
“我們之所以使用胰腺癌細(xì)胞，是因?yàn)檫@些細(xì)胞是發(fā)生在人體內(nèi)zui強(qiáng)大的，侵襲性的以及難以殺滅的癌細(xì)胞，” Kumar說。“為了表明，這種分子不僅可以阻止癌細(xì)胞擴(kuò)散，而且實(shí)際上也會(huì)導(dǎo)致它們死亡，這是非常令人興奮的。因?yàn)檫@個(gè)治療方法表明，其很有希望應(yīng)用于像胰腺癌這種侵襲性的癌癥。我們相信它也可用于其他類型的癌細(xì)胞，以及我們實(shí)驗(yàn)室正在其他類型的癌細(xì)胞中測(cè)試該治療方法。”
Kumar說，他研究的下一步是在動(dòng)物和人體試驗(yàn)發(fā)生前，尋找一個(gè)更有效的方式將該分子引入癌細(xì)胞中。
“現(xiàn)在，我們zui大的挑戰(zhàn)是，尋找一種有效的方式引入該分子，” Kumar說。“在這個(gè)時(shí)候，我們只能夠用這種分子在實(shí)驗(yàn)室中治療癌細(xì)胞。現(xiàn)在，我們使用一個(gè)更好的方法來處理動(dòng)物癌癥，看看這個(gè)治療是否真的有效。本研究的早期結(jié)果是有希望的。如果進(jìn)一步的研究，包括動(dòng)物實(shí)驗(yàn)，都成功后，下一步是將這個(gè)方法應(yīng)用于臨床試驗(yàn)。”
預(yù)后良好的患者可幸免進(jìn)行帶有嚴(yán)重副作用的侵入性治療，但不對(duì)侵入性腫瘤進(jìn)行侵入治療或可導(dǎo)致死亡。癌癥之所以致命，在很大程度上是由于其發(fā)生了轉(zhuǎn)移，從一個(gè)器官或組織轉(zhuǎn)移到另一個(gè)器官或組織。癌癥致死絕大多數(shù)與轉(zhuǎn)移有關(guān)。
對(duì)于抗原抗體癌來說，被稱為“上皮間質(zhì)轉(zhuǎn)化”的過程助推了這種轉(zhuǎn)移。上皮細(xì)胞系附著在與環(huán)境接觸的皮膚和胃腸道中。間質(zhì)細(xì)胞是胚胎組織和結(jié)締組織中的一種細(xì)胞類型，其在那里形成非常松散的。腫瘤細(xì)胞失去成熟上皮細(xì)胞的特性(如附著于環(huán)境的能力)，獲得間質(zhì)細(xì)胞的能力，使其能夠輕松地在細(xì)胞間流動(dòng)并進(jìn)入血液，從而遷移到遠(yuǎn)處的器官和組織。

西班牙

想了解更多的產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場(chǎng)部】    楊永漢

【】 
【騰訊  】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

Cancer, while always dangerous, is a real threat to life as cancer cells begin to spread to different areas and spread throughout the body. Now researchers at the University of Missouri (MU) find that a molecule that bacteria use as a communication system can be manipulated to stop cancer cells from spreading. Senthil Kumar, professor and deputy director of assistant research at the MU Veterinary Medical School's Comparative Oncology and Epigenetics Laboratory, said the communication system can be used to "l" how cancerous cells act or even die.
"During infection, bacteria release molecules so they can talk to each other," Kumar said, who led the study. "The signal ls other bacteria to breed, escape the immune system, or even stop spreading, depending on the type of molecule released, and we found that if we introduce 'stop-going' bacterial molecules into cancer cells, they not only stop spreading, but they also It will start to die. "
The study, published in PLoS ONE, by Kumar and co-author Jeffrey Bryan, an associate professor at MU Veterinary Medical School, uses a bacterial communication molecule called ODDHSL to treat human pancreas that grows in culture cancer cell. After treatment, human pancreatic cancer cells stop multiplying, fail to migrate and begin to die.
"The reason we use pancreatic cancer is because these cells are the most powerful, aggressive and hard-to-kill cancer in the body," Kumar said. "It's very exciting to show that this molecule not only stops the spread of cancer cells but actually causes them to die, as this treatment shows promise for promising invasiveness like pancreatic cancer We believe it is also available for other types of cancer cells and our laboratory is testing the treatment in other types of cancer cells. "
Kumar said the next step in his research is to find a more effective way to introduce the molecule into cancer cells before animal and human trials occur.
"Now, our biggest challenge is to find an effective way to introduce that molecule," Kumar said. "At this point, we were only able to use this molecule to treat cancer cells in the laboratory, and now we use a better approach to treating animal cancers and see if the treatment is really effective. The early results of this study were Hopefully, if further research, including animal experiments, is successful, the next step is to apply the method to clinical trials. "
Patients with good prognosis can be spared aggressive treatment with serious side effects, but not invasive treatment of invasive tumors or can lead to death. The cancer is fatal, in large part because of its metastasis, its transfer from one organ or tissue to another organ or tissue. The vast majority of cancer death and metastasis.
For antigen-antibody cancers, a process called "epithelial mesenchymal transition" helps to promote this metastasis. Epithelial cell lines attach to the environment in contact with the skin and gastrointestinal tract. Stromal cells are a type of cell in embryonic tissue and connective tissue where they form a very loose connection. Tumor cells lose the characteristics of mature epithelial cells (e.g., attached to the capacity of the environment), the ability of mesenchymal cells obtained between, it can easily flow between the cells and into the bloodstream, so migrated to distant organs and tissues.